MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2024
0mins
Source: businesswire
- MM120 Study Results: Mind Medicine (MindMed) presented data from its Phase 2b study of MM120 in treating Generalized Anxiety Disorder (GAD) at the APA Annual Meeting, showing significant efficacy compared to placebo.
- Clinical Findings: MM120 demonstrated rapid and sustained improvements in anxiety symptoms, with a 100µg dose showing optimal clinical activity and positive outcomes at Week 12.
- Secondary Endpoints: The study also assessed secondary endpoints like Montgomery-Åsberg Depression Rating Scale (MADRS) scores, indicating significant improvements in depressive symptoms.
- Safety and Tolerability: MM120 was generally well-tolerated, with mild to moderate adverse events occurring on dosing day, aligning with expected acute effects of the drug.
- Epidemiological Studies: Additional studies highlighted the underdiagnosis of GAD and its impact on individuals' quality of life, healthcare utilization, and work productivity loss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
